Research location
Rosiers-d'Égletons
France
Advertisement
Research activity in Rosiers-d'Égletons
FranceCureCurrent currently publishes aggregate city-level research activity for this location: 9 trials and 9 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Rosiers-d'Égletons
9 linked trials · page 1 of 1A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent AsthmaNCT02446418 · 2015-07-09 · 1 site observation
COMPLETED
Assessment of Comorbidities in Chronic Obstructive Pulmonary Disease (COPD) in European Symptomatic Subjects From Primary CareNCT01516528 · 2011-11-17 · 1 site observation
COMPLETED
Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary DiseaseNCT01126437 · 2010-05-01 · 1 site observation
COMPLETED
Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 DiabetesNCT01012037 · 2009-11-01 · 1 site observation
COMPLETED
Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe HypertensionNCT00860262 · 2009-03-01 · 1 site observation
COMPLETED
Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mgNCT00383929 · 2006-09-01 · 1 site observation
COMPLETED
Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic BronchitisNCT00473460 · 2004-10-01 · 1 site observation
COMPLETED
PPAR - Combination With MetforminNCT00162240 · 2003-06-01 · 1 site observation
COMPLETED
Dose Ranging Study With LT, Monotherapy, PPARNCT00240383 · 2002-05-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.